Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review,        editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name
E-mail
Phone
Title
Content
Verification Code
x Close Forever Close
Volume 35 Issue 5
. 
Turn off MathJax
Article Contents
Article Navigation >  Journal of Pharmaceutical Practice and Service  > 2017  >  35(5): 460-462,465

XU Dongli, YING Yin, LU Xuliang, SONG Hongtao, DAI Haibin. Medication analysis and pharmaceutical care for a Parkinson's disease patient with mental disorders[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(5): 460-462,465. doi: 10.3969/j.issn.1006-0111.2017.05.019
Citation: XU Dongli, YING Yin, LU Xuliang, SONG Hongtao, DAI Haibin. Medication analysis and pharmaceutical care for a Parkinson's disease patient with mental disorders[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(5): 460-462,465. doi: 10.3969/j.issn.1006-0111.2017.05.019
shu

Medication analysis and pharmaceutical care for a Parkinson's disease patient with mental disorders

doi: 10.3969/j.issn.1006-0111.2017.05.019
  • 1.

    Department of Pharmacy, Zhejiang Province Tongde Hospital, Hangzhou 310000, China

  • 2.

    Department of Pharmacy, Fuzhou General Hospital, Fuzhou 350025, China

  • 3.

    Department of Pharmacy, Second Hospital Affiliated to College of Medicinal Sciences, Zhejiang University, Hangzhou 310009, China

  • Received Date: 2016-03-03
  • Rev Recd Date: 2016-09-06
  • Objective To investigate the role of clinical pharmacists in the treatment of a Parkinson's disease patient with mental disorders. Methods Clinical pharmacists provided appropriate pharmaceutical care and optimized the treatment program based on patient's symptom, medication history, drug interactions,and adverse drug reactions etc. Results Clinical pharmacists improved rational drug use by participating in the development of patient's treatment program, giving patient with proper medication instruction and discharge education. Conclusion With their professional knowledge, clinical pharmacists play an important role in rational drug use and helping physicians to optimize the medication regimen.
  • [1] 中华医学会神经病学分会帕金森病及运动障碍学组. 中国帕金森病治疗指南(第三版)［J］. 中华神经科杂志, 2014, 47(6):428-433.
    [2] 王惠霞,武新安,何忠芳. 帕金森病一例药学监护实践［J］. 临床合理用药杂志, 2012,12(5): 85-86.
    [3] Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines［S］. Neurology, 2001,56(11): S1-S88.
    [4] 刘春风,尹伟华,罗蔚锋.帕金森病患者运动障碍和症状波动的影响因素［J］.中华神经科杂志,2003, 36(6): 411-413.
    [5] Zhang ZX, Chen H, Chen SD, et al.Chinese culture permeation in the treatment of Parkinson disease:a cross-sectional study in four regions of China［J］. BMC Res Notes, 2014, 7: 65.
    [6] Warren Olanow C, Kieburtz K, Rascol O, et al. Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease［J］. Mov Disord, 2013, 28(8):1064-1071.
    [7] 中华医学会神经病学分会神经心理学与行为神经病学组, 中华医学会神经病学分会神经心理学与行为神经病学组. 帕金森病抑郁、焦虑及精神病性障碍的诊断标准及治疗指南［J］.中华神经科杂志,2013,46(1):56-60.
    [8] 江开达.中华医学会精神科分会.抑郁障碍防治指南［M］.北京:北京大学医学出版社,2007:21.
    [9] Barone P,Poewe W,Albrecht S,et al.Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease:a randomised,double-blind,Placebo-controlled trial［J］.Lancet Neurol,2010,9(6):573-580.
    [10] O'Sullivan SS, Williams DR, Gallagher DA, et al. Nonmotor symptoms as presenting complaints in Parkinson's disease: a clinicopathological study［J］. Mov Disord, 2008, 23(1): 101-106.
    [11] Duncan GW, Khoo TK, Yarnall AJ, et al. Health-related quality of life in early Parkinson's disease: the impact of nonmotor symptoms［J］. Mov Disord, 2014, 29(2):195-202.
    [12] Shiba M, Bower JH, Maraganore DM, et al. Anxiety disorders and depressive disorders preceding Parkinson's disease: a case-control study［J］. Mov Disord, 2000,15(4): 669-677.
    [13] Leentjens AF, Van den Akker M, Metsemakers JF, et al. Higher incidence of depression preceding the onset of Parkinson's disease: a register study［J］. Mov Disord, 2003,18(4): 414-418.
    [14] Gonera EG, van't Hof M, Berger HJ, et al. Symptoms and duration of the prodromal phase in Parkinson's disease［J］. Mov Disord, 1997,12(6): 871-876.
    [15] Shen CC,Tsai SJ, Perng CL, et al. Risk of Parkinson disease after depression: a nationwide population-based study［J］. Neurology,2013, 81(17): 1538-1544.
    [16] Breier A, Sutton V, Feldman PD, et al. Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease［J］. Biol Psychiatry,2002, 52(5): 438-445.
    [17] Ondo WG, Levy JK, Vuong KD, et al. Olanzapine treatnlent for dopaminergic-induced hallucinations［J］. Mov Disord, 2002, 17(5):1031-1035.
    [18] Goetz CG, Blasucci LM, Leurgans S, et al. Olanzapine and clozapine:comparative effects on motor function in hallucinating PD patients［J］. Neurology,2000, 55(6): 789-794.
    [19] Friedman JH. Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease［J］. Neuorlogy,1998, 50(4):1195-1196.
    [20] Seppi K, Weintraub D, Coelho M, et a1. The movement disorder society evidence-based medicine review update:treatments for the non-motor symptoms of Parkinson's disease［J］. Mov Disord,2011, 26(3): S42-80.
  • 加载中
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索
Get Citation
PDF
XML

Article Metrics

Article views(2747) PDF downloads(950) Cited by()

Related
Proportional views

Medication analysis and pharmaceutical care for a Parkinson's disease patient with mental disorders

doi: 10.3969/j.issn.1006-0111.2017.05.019
  • 1. Department of Pharmacy, Zhejiang Province Tongde Hospital, Hangzhou 310000, China
  • 2. Department of Pharmacy, Fuzhou General Hospital, Fuzhou 350025, China
  • 3. Department of Pharmacy, Second Hospital Affiliated to College of Medicinal Sciences, Zhejiang University, Hangzhou 310009, China
  • Received Date: 2016-03-03
  • Rev Recd Date: 2016-09-06

Abstract: Objective To investigate the role of clinical pharmacists in the treatment of a Parkinson's disease patient with mental disorders. Methods Clinical pharmacists provided appropriate pharmaceutical care and optimized the treatment program based on patient's symptom, medication history, drug interactions,and adverse drug reactions etc. Results Clinical pharmacists improved rational drug use by participating in the development of patient's treatment program, giving patient with proper medication instruction and discharge education. Conclusion With their professional knowledge, clinical pharmacists play an important role in rational drug use and helping physicians to optimize the medication regimen.

XU Dongli, YING Yin, LU Xuliang, SONG Hongtao, DAI Haibin. Medication analysis and pharmaceutical care for a Parkinson's disease patient with mental disorders[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(5): 460-462,465. doi: 10.3969/j.issn.1006-0111.2017.05.019
Citation: XU Dongli, YING Yin, LU Xuliang, SONG Hongtao, DAI Haibin. Medication analysis and pharmaceutical care for a Parkinson's disease patient with mental disorders[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(5): 460-462,465. doi: 10.3969/j.issn.1006-0111.2017.05.019
shu

    HTML

Reference (20)

Catalog

    版权所有：《药学实践与服务》编辑委员会

    Supervisor & Sponsors: Address: No 325 Guohe Road, ShanghaiPost Code: 200433

    Tel: （021）81871324,81871397 E-mail: yxsjzzs@163.com

    网站备案号 沪ICP备05003363号-1

    Supported by: Beijing Renhe Information Technology Co., Ltd.  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return